Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
复制标题
对黑色素瘤患者皮内注射 BEC2-匙孔血蓝蛋白加卡介苗进行免疫，然后用 BEC2 进行静脉内加强免疫，以诱导抗 GD3 神经节苷脂抗体。
作者：
T. Yao;M. Meyers;Philip S. Livingston;A. Houghton;P. Chapman
BEC2 是一种模拟 GD3 神经节苷脂的抗独特型小鼠单克隆抗体。先前的临床试验表明，使用 2.5 毫克 BEC2 与卡介苗或静脉注射进行皮内免疫可以有效地预防和预防感染。使用 10 mg BEC2 进行免疫可以在一部分患者中诱导抗 GD3 抗体。我们假设，结合这两种免疫策略可能更有效地诱导抗 GD3 抗体，并且 BEC2 与匙孔血蓝蛋白 (KLH) 的缀合将进一步增强 BEC2 的免疫原性。在这项临床试验中，18名在1-6个月内完全手术切除后无疾病的黑色素瘤患者在第0、2、4、6和10周接受了2.5 mg与KLH缀合的BEC2并与BCG混合（BEC2-KLH/BCG）的皮内免疫。静脉注射 10 mg 未缀合的 BEC2 加强免疫。第 24、37 和 50 周。18 名患者中有 4 名 (22%) 出现了 IgM 抗 GD3 抗体。未检测到 IgG 抗 GD3 抗体。所有四名有反应的患者在使用 BEC2-KLH/BCG 免疫期间均出现抗 GD3 IgM；只有一名患者在静脉注射期间表现出 IgM 抗 GD3 滴度重新增强。免疫接种。其中 13 名患者没有出现黑色素瘤（其中 3 名患者因局部复发而接受再次切除手术后）；中位随访 28 个月后，14 名患者 (78%) 仍然存活。这些结果证实了我们之前的试验，表明 BEC2 与 BCG 可以在患者体内诱导抗 GD3 抗体。数据并未提供证据表明，当与 BEC2 与 BCG 一起施用时，与 KLH 的缀合会增加 BEC2 的免疫原性。
BEC2 is an anti-idiotypic mouse monoclonal antibody that mimics GD3 ganglioside. Previous clinical trials demonstrated that intradermal immunization using 2.5 mg of BEC2 with BCG or i.v. immunization with 10 mg of BEC2 can induce anti-GD3 antibodies in a subset of patients. We hypothesized that combining these two immunization strategies might be more effective in inducing anti-GD3 antibodies and that conjugation of BEC2 to keyhole limpet hemocyanin (KLH) would further enhance the immunogenicity of BEC2. In this clinical trial, 18 melanoma patients who were free of disease after complete surgical resection within 1-6 months received intradermal immunizations on weeks 0, 2, 4, 6, and 10 with 2.5 mg of BEC2 conjugated to KLH and mixed with BCG (BEC2-KLH/BCG). Booster immunizations of 10 mg of unconjugated BEC2 were administered i.v. on weeks 24, 37, and 50. Four of 18 patients (22%) developed IgM anti-GD3 antibodies. No IgG anti-GD3 antibodies were detected. All four responding patients developed anti-GD3 IgM during immunization with BEC2-KLH/BCG; only one patient demonstrated a reboost of the IgM anti-GD3 titer during the i.v. immunizations. Thirteen of the patients are free of melanoma (3 after undergoing re-resection for local relapse); 14 patients (78%) remain alive with a median follow-up of 28 months. These results confirm our previous trial, showing that BEC2 with BCG can induce anti-GD3 antibodies in patients. The data do not provide evidence that conjugation to KLH increases the immunogenicity of BEC2 when it is administered with BCG.
DOI：
10.1073/pnas.89.2.466
发表时间：
1992-01-15
影响因子：
11.1
作者：
MITTELMAN, A;CHEN, ZJ;FERRONE, S
通讯作者：
FERRONE, S
使用模拟 GD3 神经节苷脂的 BEC2 抗独特型单克隆抗体对黑色素瘤患者进行免疫：与佐剂联合使用可增强免疫原性。
DOI：
--
发表时间：
1996
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
--
作者：
McCaffery,M;Yao,TJ;Williams,L;Livingston,PO;Houghton,AN;Chapman,PB
通讯作者：
Chapman,PB